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Abstract
Background: Cardiac resynchronization therapy‐defibrillator (CRT‐D) implantation
via the cephalic vein is feasible and safe. Recent evidence has suggested a higher
implantable cardioverter‐defibrillator (ICD) lead failure in multi‐lead defibrillator
therapy via the cephalic route. We evaluated the relationship between CRT‐D
implantation via the cephalic and ICD lead failure.
Methods: Data was collected from three CRT‐D implanting centers between
October 2008 and September 2017. In total 633 patients were included. Patient
and lead characteristics with ICD lead failure were recorded. Comparison of
“cephalic” (ICD lead via cephalic) versus “non‐cephalic” (ICD lead via non‐cephalic
route) cohorts was performed. Kaplan–Meier survival and a Cox‐regression analysis
were applied to assess variables associated with lead failure.
Results: The cephalic and non‐cephalic cohorts were equally male (81.9% vs. 78%;
p = .26), similar in age (69.7 ± 11.5 vs. 68.7 ± 11.9; p = .33) and body mass index
(BMI) (27.7 ± 5.1 vs. 27.1 ± 5.7; p = .33). Most ICD leads were implanted via the
cephalic vein (73.5%) and patients had a mean of 2.9 ± 0.28 leads implanted via this
route. The rate of ICD lead failure was low and statistically similar between both
groups (0.36%/year vs. 0.13%/year; p = .12). Female gender was more common in
the lead failure cohort than non‐failure (55.6% vs. 17.9%, respectively; p = .004) as
was hypertension (88.9% vs. 54.2%, respectively, p = .038). On multivariate Cox‐
regression, female sex (p = .008; HR, 7.12 [1.7−30.2]), and BMI (p = .047; HR, 1.12
[1.001−1.24]) were significantly associated with ICD lead failure.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Journal of Cardiovascular Electrophysiology Published by Wiley Periodicals LLC
Abbreviations: AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; F, female; HTN, hypertension; IBD, inflammatory
bowel disease; ICD, implantable cardioverter defibrillator; IHD, ischemic heart disease; M, male.
Conclusion: CRT‐D implantation via the cephalic route is not significantly associated
with premature ICD lead failure. Female gender and BMI are predictors of lead failure.
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1 | INTRODUCTION
The cardiac resynchronization therapy‐defibrillator (CRT‐D) is an estab-
lished treatment for heart failure which reduces morbidity and mortal-
ity.1 The pacing leads are predominantly implanted via the transvenous
approach, usually by subclavian or axillary puncture and sometimes by
cephalic vein cut‐down. There is no standard approach, but cephalic ac-
cess is feasible, effective, and safe2,3 irrespective of the number of leads
being implanted.4 Traditional lateral subclavian vein puncture has been
associated with a higher rate of lead failure than the use of cephalic
venous access5,6 but a recent report has suggested that multi‐lead defi-
brillator therapy utilizing the cephalic route is associated with early im-
plantable cardioverter‐defibrillator (ICD) lead failure.7
2 | METHODS
Data were collected retrospectively for patients with a CRT‐D
implant between October 2008 and September 2017 from three
centers. The follow‐up duration was determined from implanta-
tion to either lead failure, patient death, or end of the study
period. The implantation technique varied among the 12 opera-
tors. A minority of operators used venogram‐guided lateral
axillary (or subclavian) access as the method of the first choice.
Cephalic cut‐down was preferred by most operators and has been
reported previously.2,4 Following isolation of the cephalic vein
with blunt dissection close to the level of the coracoid process, the
distal end of the vein was tied and a precise transverse venotomy
was performed at this anatomical level. Two standard 50 cm
0.97 mm guidewires and a 150 cm angled 0.97 mm hydrophilic
guidewire (Radiofocus RF*GA35153M, Terumo Corporation) were
introduced and advanced towards the heart. Initially, the coronary
sinus (CS) delivery system was advanced over the hydrophilic
guidewire, to position the CS lead (with contrast venogram) in a
suitable cardiac vein. Peel‐away sheaths were then used to posi-
tion an atrial lead (7 fr sheath) and an ICD ventricular lead
(9 fr sheath). When this vessel was too small to allow access to all
the leads, either the axillary or subclavian was used for the re-
mainder. It was at the operator's discretion to decide which lead
to place by other routes of access.
Pacing interrogation was performed within 24 h after implanta-
tion, at 6 weeks, and subsequently at 6‐month intervals. Patients
F IGURE 1 Bar graph demonstrating the distribution of implant routes for other leads according to the implantation route of the high‐
voltage lead (A, B) and the distribution of access route for high voltage leads according to lead model (C). All systems included a left ventricular
lead; 91% included an atrial lead. (A) When the high‐voltage lead was implanted via the cephalic vein, the other leads followed the same
route in 98.7% of cases. (B) When the ICD lead was non‐cephalic, 78.6% of the other leads were also non‐cephalic. (C) The Sprint Quattro
(Medtronic) and the Endotak Reliance (Boston Scientific) leads were used in the majority of our population with a similar distribution of cephalic
and non‐cephalic access used across all lead models. ICD, implantable cardioverter‐defibrillator
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with defibrillator leads implanted via the cephalic vein were cate-
gorized as the “cephalic” group and patients in whom the defibrillator
lead was implanted utilizing the subclavian or axillary veins, were
categorized as the “non‐cephalic” group.
2.1 | Lead failure
Lead failure was defined as per the Heart Rhythm Society consensus.8
High‐voltage leads were considered to have failed if they exhibited:
persistent oversensing of non‐physiological rapid signals, the abnormal
impedance in the pace/sense or the shock component, an increase in
right‐ventricular lead threshold, and/or decrease in sensing sufficient to
make the lead unreliable.8 All leads that met these criteria were ex-
tracted and replaced; all were inspected carefully before and after ex-
traction. Lead extraction for infection and lead revision for displacement
were considered separately. Radiological images from the time of im-
plantation were inspected for all leads that subsequently failed.
2.2 | Statistical analysis
Continuous variables were conveyed as a mean ± standard deviation
and median with interquartile range (IQR), whilst categorical
variables were presented as a number and percentage. Statistical
analysis was performed using a χ2 test and an independent t test. A
p < .05 was considered significant. Lead longevity was analyzed using
the Kaplan–Meier model and risk factors were compared using a
univariate, multi‐variate, and Cox regression analysis.
3 | RESULTS
Over the study period, 633 patients underwent CRT‐D therapy and were
included in the analysis. In most cases (73.5%), the high‐voltage lead was
implanted via the cephalic vein (cephalic group) while the remainder
were axillary (21.9%) and subclavian (4.6%) access; the majority (50.3%)
of the implanted ICD leads were Sprint Quattro (Medtronic) (Figure 1).
Both groups were predominantly male (81.9% vs. 78%, respectively;
p= .26) of a similar age (69.7 ± 11.5 years vs. 68.7 ± 11.9, respectively;
p= .33) and had a left‐sided implant (96.6% vs. 97%; p= .72) for primary
prevention (91.2% vs. 92.9%; p= .5). Co‐morbidities in both groups were
fairly similar (Table 1) although chronic kidney disease was more pre-
valent in the cephalic group (16.3% vs. 10.1%, respectively; p= .05). The
mean follow‐up period was 4.75 ±2.4 years. The overall lead failure rate
in this study was 0.3%/year.
During the study period, 20 patients required revision or
replacement of the RV lead. Of these, six (30%) patients had an infection
indication, including erosion, local infection, and systemic sepsis. Early
lead replacement for displacement or cardiac perforation accounted for 4
(20%) cases and the remaining 10 (50%) were premature lead failures.
High‐voltage lead failure was rare; failure occurred at a non-
significant higher rate of 0.36% per year in the cephalic group (8 of
462 implants), in comparison to the 0.13% per year in the non‐
cephalic group (1 of 171 implants) (p = .12; Figure 2). There was no
significant difference in the failure rate of individual lead models
(Sprint Quattro, Endotak Reliance, Linox; 0.27%/year, 0.2%/year,
0.41%/year, respectively; p = .82) (Figure 3). The number of shock
coils, the number of concomitant leads implanted with the defi-
brillator lead and the ICD lead tip position within the right ventricle,
did not affect lead longevity (Figure 2). However, ICD leads im-
planted in female patients for CRT‐D, were more likely to experience
premature failure (p = .018) (Figure 4).





N 465 (73.5%) 168 (26.5%) <.001
Male 381 (81.9%) 131 (78%) .26
Age 69.7 ± 11.5 68.7 ± 11.9 .33
Number of leads 2.91 ± 0.35 2.88 ± 0.32 .4
BMI 27.7 ± 5.1 27.1 ± 5.7 .33
Ischemic
cardiomyopathy
347 (74.6%) 125 (74.4%) .96
IHD 339 (72.9%) 120 (71.4%) .72
Diabetes 118 (25.4%) 49 (29.2%) .34
CKD 76 (16.3%) 17 (10.1%) .05
Hypertension 257 (55.3%) 89 (53%) .61
Atrial fibrillation 168 (36.1%) 54 (32.1%) .35
LVEF (%) 28.4 ± 8.2 28.4 ± 8.6 .96
Procedure (min) 120.6 ± 46.6 143.9 ± 44.8 <.001
RV lead failure 8 (1.72%) 1 (0.6%) .29
Lead follow‐up
(months) to failure,
death, or study end
58.7 ± 30.1 52.2 ± 24.6 .006
Left sided implant 449 (96.6%) 163 (97%) .72
Primary prevention 424 (91.2%) 156 (92.9%) .5
Single coil 217 (46.7%) 99 (58.9%) <.01
Dual coil 248 (53.3%) 69 (41.1%) <.01
Sprint Quattro 234 (50.3%) 79 (47%) .9
Endotak reliance 159 (34.2%) 59 (35.1%) .9
Linox 32 (6.9%) 13 (7.7%) .9
Other leads 40 (8.6%) 17 (10.1%) .9
Note: On average a statistically significantly higher number of leads were
implanted via the cephalic, than non‐cephalic routes. The procedure was
also noted to be longer in the non‐cephalic procedures. However, there
was no significant difference in the number of ICD lead failures between
the two groups (p = .29).
Abbreviations: BMI, body mass index; CDK, chronic kidney disease;
ICD, implantable cardioverter defibrillator; IHD, ischemic heart disease;
LVEF, left ventricular ejection fraction.
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F IGURE 2 Kaplan–Meier curves describing lead survival. (A) No significant difference in survival of ICD leads was detected between those
implanted via the cephalic and non‐cephalic routes. (B) ICD lead implanted in septal and apical locations lasted equally well. (C) Durability
of the ICD lead was not influenced by the number of leads implanted via the cephalic vein. (D) The number of coils of the implanted ICD lead
does not affect lead longevity. ICD, implantable cardioverter‐defibrillator
3.1 | Comparison of lead failure and non‐failure
cohorts
Comparison of the ICD lead failure and non‐failure cohorts was per-
formed for baseline patient characteristics (Table 2). There was a sig-
nificantly higher proportion of female (55.6% vs. 17.9%; p= .004) and
hypertensive patients (88.9% vs. 54.2%; p= .038) in the lead failure group.
There was a trend toward patients of higher body mass index (BMI) (31.7
vs. 27.4; p= .17) and toward a longer implantation procedure duration
(137.4 vs. 126.5min; p= .7) in the lead failure group. A similar proportion
of ICD leads were implanted via the cephalic in lead failure and non‐failed
groups (88.9% vs. 73.2%; p= .24). When the ICD lead was implanted via
the cephalic vein, a statistically similar number of leads were implanted
via this route concomitantly, in both cohorts (2.56 vs. 2.83, lead failure vs.
non‐failure, respectively; p= .43).
3.2 | Predictors of lead failure
A univariate logistic regression analysis of the whole study popula-
tion was performed for predictors of lead failure (Supporting
Information). Female gender (p = .012; OR, 5.52 [1.46–20.9]) and BMI
(p = .03; OR, 1.12 [1.01–1.25]) were significant factors, whilst
hypertension was correlated although it did not reach statistical
significance (p = .072; OR, 6.8 [0.84–54.4]). When entered in to a Cox‐
regression analysis, female gender (p = .008; HR, 7.12 [1.7–30.2]) and
BMI (p = .047; HR, 1.12 [1.001–1.24]) were significant predictors of
lead failure (Table 3). Hypertension although correlated, did not
reach statistical significance as a predictor of lead failure (p = .051;
HR, 8.74 [0.99–77.4]).
4 | DISCUSSION
The current series is the largest to date evaluating the
relationship between multi‐lead defibrillator therapy delivered
via the cephalic vein, and ICD lead failure. We found a very low
incidence of lead failure in this solely CRT‐D based study
(0.3%/year). The findings have important practical applications
as CRT‐D system implantations via the cephalic are efficient
and safe,4 while ICD lead failures maintain a degree of
concern.7
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This multi‐center study reported a very low overall lead fail-
ure rate which is at odds with some previous series7 but is vali-
dated by a previous large series (0.45%/year).9 This low failure
rate may reflect our conservative practice: a policy of
concentrating on products with a track record of long‐term safety
and late adoption of less tested technology. The higher incidence
of failure in the prior literature may represent a publication bias; it
is reasonable to suppose that colleagues are more likely to report
an unsatisfactory experience than to describe a lead performance
that is in line with expectation.
This series demonstrates that cephalic vein access for
multi‐lead defibrillator therapy does not affect ICD lead longevity: the
rate of lead failure was similarly low for cephalic and non‐cephalic routes
(0.36%/year vs. 0.13%/year; p= .12). This is in stark contrast to a recent
report by Barbhaiya et al.7 which found that cephalic access was sig-
nificantly associated with a high rate of lead failure in multi‐lead ICD
therapy (11% per year for non‐Linox and 19% per year for Linox leads).
There are significant differences between the two reports. Their method
was to implant a maximum of two leads via the cephalic vein, whereas
most of our patients received three leads by this route. Barbhaiya et al
described only 46% of their cohort as having multi‐lead ICD systems, our
study population consists entirely of CRT‐D devices (≥2 leads). They
implanted only 18% of ICD leads via the cephalic vein, while we used it in
73.5%. This implies that their series included only around 55 ICD leads
implanted via the cephalic as part of a multi‐lead system compared to
465 in our series.
Our data include a trend toward a higher rate of ICD lead fail-
ures in the cephalic group but it is well within the margin of error;
F IGURE 3 Kaplan–Meier survival curves of lead models. There was no significant difference in lead longevity of the three most frequently
used leads at our institutes (A). The mode of venous access had no statistically significant effect on the survival of the Sprint Quattro
(B), Endotak Reliance (C) or Linox (D) high‐voltage leads
F IGURE 4 Kaplan–Meier curve of ICD lead survival by gender.
The rate of defibrillator lead survival was significantly poorer in
female patients, compared to their male counterparts (p = .018).
ICD, implantable cardioverter‐defibrillator
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the use of non‐cephalic access is too unusual in our series to permit
us to analyze the difference. The sample size for cephalic implants is
far larger and is sufficient to demonstrate clearly that the high failure
rate of high voltage leads implanted via cephalic access as part of
multi‐lead systems reported by Barbhaiya et al is not reproduced in
the center contributing to our series.
Sample size alone cannot account for the contrast between
our results and those of Barbhaiya et al. As their series included
just six instances of lead failure including four (67%) implanted via
the cephalic route, the association may have been a chance event
detected on post‐hoc analysis. Inter‐institution differences in im-
plantation technique could also have played a role: Barbhaiya
et al.10 demonstrated that the phenomenon they described was
not attributable to a single operator, but institutional culture de-
termines the idiosyncrasies of operative technique as much as
interindividual variation. All of the predominantly cephalic op-
erators in our series derived at least part of their methodology
from one mentor.
We believe that many small technical11 and methodological
differences could play a role in lead durability: for example, our
policy is to place all leads via peel‐away sheaths to protect the tip
from stress produced by passage through a tortuous cephalic vein. In
our series, 75% of the operators would be considered as “cephalic‐
operators” with a similar well‐honed technique and experience in
accessing this vein, maintaining consistency, and minimizing error. It
can be argued this may skew the findings, but it represents a multi‐
institutional experience that is consistent and reproducible with
favorable outcomes.
Our population included a low proportion of leads that are
associated with a high rate of failure (Table 4). The Sprint Fidelis
(Medtronic) had been withdrawn before the study recruitment
period; the Riata was seldom used in our centers. The
Linox (Biotronik) which has been associated with an elevated
failure rate in some series12,13 but not all7,14 demonstrated
similar performance to other models, but the comparison
is underpowered.
The Cox regression analysis found that the venous access
route does not predict lead failure (p = .5), in keeping with prior
reports.15 Consistent with previous findings, we found leads im-
planted in women were much more likely to fail16 (Figure 4). The
naturally smaller female frame may enforce tighter angulation
within the thoracic vasculature, applying stress on the implanted
leads. Due to their smaller size, women are also more likely to
have excess redundant lead folded within the pocket, increasing
lead tension at this site.
There was an obvious trend indicating an association
between hypertension and premature lead failure in our series
but due to a small number of lead failure events, it did not reach
statistical significance (p = .051). It stands to reason as a hazard
to lead durability: Hypertension results in shear stress on the
vascular system leading to remodeling with increased tortuosity
and angulations in the arterial system. The venous system is
not directly altered by arterial hypertension, but the close
anatomic relationship could expose venous leads indirectly to
stress arising from the angulations of the associated arteries
(Figure 5).
4.1 | Limitations
This study was a retrospective analysis and therefore open to bias
from confounding variables. Remote monitoring was available only
for a minority of devices across the study period and may result in






Age 64 ± 9.7 69.5 ± 11.6 .13
Female 55.6% 17.9% .004
Implantation procedure
duration (min)
137.4 ± 82.1 126.5 ± 46.6 .7
Ischemic heart disease 66.7% 72.6% .69
Diabetes 22.2% 26.4% .78
Chronic kidney disease 0 14.9% .21
Hypertension 88.9% 54.2% .038
Atrial fibrillation 22.2% 35.3% .41
Body mass index 31.7 ± 8 27.4 ± 5.2 .17
Left ventricular ejection
fraction (%)
26.1 ± 5.7 28.4 ± 8.3 .33
Lead age to failure or end
of follow‐up (months)
49.6 ± 31.1 57.1 ± 28.9 .49
Cephalic access (%) 88.9% 73.2% .24
Number of cephalic leads
when ICD lead
cephalic
2.56 ± 1 2.83 ± 0.4 .43
Abbreviation: ICD, implantable cardioverter defibrillator.
TABLE 3 Cox‐regression analysis for variates of lead failure
Variable Hazard ratio 95% CI p value
Female gender 7.124 1.68–30.208 .008
Hypertension 8.744 0.988–77.418 .051
Body mass index 1.116 1.001–1.243 .047
ICD lead cephalic access 2.056 0.247–17.144 .505
Abbreviations: CI, confidence interval; ICD, implantable cardioverter‐
defibrillator.
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underestimation of lead failure, although the open‐access pacing
clinic accounted for this to reasonable effect. Due to relatively
smaller sample size for non‐cephalic access, propensity matching
could not be performed.
5 | CONCLUSION
Cephalic vein access for multi‐lead ICD therapy is not a significant
risk factor for lead failure in the long‐term. Our data confirm that
female gender and BMI are predictors of lead failure.
F IGURE 5 Examples of radiographic images from fluoroscopy stored at the time of implantation for patients who subsequently experienced
lead failure. The numbering of patients corresponds to the order of implantation and the numbering in Table 4. (A) Corresponding to
Patient 2. (B) and (C) Corresponding to Patient 3. (D) Corresponding to Patient 4. (E) Patient number 5. (F) Patient 6. (G) Patient number
7 with tortuosity of the innominate vein. (H) Venogram of Patient 8 demonstrating a large cephalic vein (dotted arrow) which was not used;
instead, the system was implanted by lateral axillary puncture (solid arrow). (I) Corresponding to Patient 9
1138 | AKHTAR ET AL.
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